We recently assessed a cohort of CHC patients and reported a proteomic signature of HCV treatment response measured in pre-treatment serum samples that was highly predictive of response to peg-interferon/Ribavirin [11], with equivalent performance to IL28B genotype. The gene discussed is IFNL3; the disease is cryohydrocytosis.